ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,533,399, issued on Jan. 27, was assigned to ANTUREC PHARMACEUTICALS GMBH (Frankfurt am Main, Germany).
"Composition comprising tTF-NGR for use in treating soft-tissue sarcoma" was invented by Wolfgang E. Berdel (Munster, Germany).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides compositions comprising Trabectedin or a tTF-NGR protein for use in the treatment of cancer in an individual, wherein the treatment comprises the following steps: (a) administering to the individual an effective amount of a composition comprising Trabectedin, and (b) subsequently administering to the individual an effective amount of a composition comp...